[LincolnCream]

Zoya Demidenko: Researcher in Cancer Studies
Zoya Demidenko is a prominent investigator connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she was employed at the National Institutes of Health and New York Medical College, building a robust base in biomedical research.
Her academic work spans several critical areas, including the PI3K/AKT/mTOR signaling pathway, cellular cycle management, cellular aging, and tumor biology. As of now, she has co-authored over 46 peer-reviewed articles, which have received more than 4,100 references — a indicator to the impact of her research.
Among her key achievements involves explaining the mechanisms of cell aging. Her studies revealed that when the cell cycle is blocked but cellular growth proceeds, the cells undergo senescence. Significantly, Zoya Demidenko established that this shift can be inhibited by medication using substances such as mTOR inhibitors.
Zoya Demidenko has furthermore added substantially to tumor management research, particularly in the area of selective cell protection — a strategy designed to safeguarding normal tissue from cytotoxic treatment whilst leaving tumor cells vulnerable. This method holds significant hope for lowering the toxic effects of cancer treatment.
Across her professional journey, Demidenko has collaborated with prominent investigators worldwide, including Dr. Mikhail Blagosklonny. Her research is published in prestigious periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a influential voice in current biomedical science, whose findings go on to guide our knowledge of the way biological cells age, respond to treatment, and how cancer can be better treated.
https://journals.plos.org/plosone/ar...l.pone.0026126